TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02915484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.
Study: NCT00862719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
Study: NCT01228253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS: repetitive transcranial magnetic stimulation
Description: patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM rTMS: repetitive transcranial magnetic stimulation is off
Description: patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
Study: NCT02436434

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)
Description: Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)
Description: Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
Study: NCT03187964

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PLHIV Point of Care Xpert Ultra
Description: Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PLHIV Point of Care Xpert VL
Description: Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
Study: NCT00798590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide-1
Description: 5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
Study: NCT00324116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium (Macugen)
Description: 0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
Study: NCT03878277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Starbucks® Cold brew - 325ml bottle
Description: Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
Study: NCT00357331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: potassium citrate
Description: 20 meq by mouth in capsule form twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium citrate
Description: 20 meq by mouth in capsule form twice daily
Study: NCT03245151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension
Study: NCT00469690

Intervention type: DRUG
Group type: OTHER
Intervention: Acular, Xibrom
Description: 1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)

Intervention type: DRUG
Group type: OTHER
Intervention: Acular, Xibrom
Description: 1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)
Study: NCT03117829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Diet and Exercise Study to Improve Brain Blood Flow
Study: NCT03312816

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cookies enriched with POP
Description: Cookies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cookies enriched with POP
Description: Cookies
Study: NCT01917279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel plus Capecitabine
Description: Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
Study: NCT04385381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URECA CTO device
Description: facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
Study: NCT01917279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Capecitabine
Description: Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Capecitabine
Description: Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Capecitabine
Description: Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
Study: NCT06284499

Intervention type: OTHER
Intervention: measuring tooth stability after orthodontic treatment using a Periotest® device.
Description: The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.

Intervention type: OTHER
Intervention: measuring tooth stability after orthodontic treatment using a Periotest® device.
Description: The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.
Study: NCT00599703

Intervention type: OTHER
Intervention: fMRI Scan, pre- and post language evaluation
Description: All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
Study: NCT04573088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCEPTANCE-BASED INTERVENTION
Description: 24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
Study: NCT04303715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No SLNB
Description: BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLNB
Description: BCS with SLNB(+/-ALND)
Study: NCT04127851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-018 (HA 0.15%)
Description: TJO-018 / one drop / 6 times daily in both eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)
Description: Cyclosporine / one drop / twice daily in both eyes carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes

Intervention type: DRUG
Group type: OTHER
Intervention: TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
Description: TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes
Study: NCT03017898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Coagulation
Description: Laser coagulation of anal fistula
Study: NCT01226342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical muscle stimulation
Description: On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
Study: NCT02217475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: CVC 150 mg, administered orally once daily and taken every morning with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: CVC 150 mg, administered orally once daily and taken every morning with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily and taken every morning with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once daily and taken every morning with food.
Study: NCT01288300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Picture good health/Imaginate una buena salud
Description: Diabetes education, self-empowerment training, exercise, patient navigator

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes lecture
Description: Diabetes self-management lecture
Study: NCT02402374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma gel
Description: PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
Study: NCT02175121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 15 mg, once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 35 mg, once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 75 mg, once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 150 mg, once daily for 28 days
Study: NCT02900742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiYangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine®
Description: Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine®
Description: Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed®
Description: Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed®
Description: Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel®
Description: Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel®
Description: Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo granules
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Study: NCT03242317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
Study: NCT03525392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-3BP-227 (also called 177Lu-IPN01087)
Description: The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
Study: NCT01296802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexfenfluramine
Description: oral, 40 mg to 60 mg, single application as a challenge
Study: NCT04168034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iParent2Parent Program
Description: In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: The control group will receive standard care but without the iParent2Parent program
Study: NCT02484014

Intervention type: OTHER
Group type: OTHER
Intervention: Tarang Adolescence Education programme
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tarang Adolescence Education programme
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tarang Adolescence Education programme
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEHER Intervention
Description: The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEHER Intervention
Description: The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year.
Study: NCT02060357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical coherence tomography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical coherence tomography
Study: NCT02517658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watching a YouTube video containing post tonsillectomy discharge instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watching a YouTube video containing post tonsillectomy discharge instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard discharge teaching
Description: Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard discharge teaching
Description: Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
Study: NCT00652444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Unspecified)
Description: Matching ezetimibe placebo